Skip to main content
Clinical Trials/NCT05713981
NCT05713981
Completed
Not Applicable

The Impact of Dry Eye Syndrome on Novel Metrics of Low Contrast Vision Before and After Therapeutic Meibomian Gland Expression

University of the Incarnate Word1 site in 1 country40 target enrollmentMarch 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Meibomian Gland Dysfunction
Sponsor
University of the Incarnate Word
Enrollment
40
Locations
1
Primary Endpoint
Change in Response Time on Cone Contrast Test (CCT, Innova Systems, Inc.)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The study aims to determine the impact of Meibomian Gland Dysfunction (MGD) dry eye on low contrast black/white (luminance) and cone color sensitivity performance and improvement in these functions after in-house non-invasive Meibomian gland (MG) expression.

Detailed Description

This study offers possible benefits from gland expression to patients and subjects in terms of clinical measurements and care associated with meibomian gland dysfunction impacting all age ranges. Prior studies show that these interventions improve dry eye symptoms with intent to improve vision, low contrast color, and B/W vision after intervention in this study.

Registry
clinicaltrials.gov
Start Date
March 1, 2023
End Date
June 8, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

JEFFREY CARL RABIN

Professor and Assistant Dean for Graduate Studies, Research and Assessment and Chief, Visual Neurophysiology Service

University of the Incarnate Word

Eligibility Criteria

Inclusion Criteria

  • Individuals over the age of 18 years
  • Healthy individuals with reported symptoms of dry eye such as burning, stinging, fluctuating vision, inappropriate tearing, and feelings of grittiness particularly with prolonged near work

Exclusion Criteria

  • Under the age of 18
  • Individuals currently using prescription eye medications for dry eye / MGD / inflammation / Infections or any other treatments.

Outcomes

Primary Outcomes

Change in Response Time on Cone Contrast Test (CCT, Innova Systems, Inc.)

Time Frame: This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.

This computer test measures average response time in seconds to see red, green and blue low contrast letters.

Change in Cone Contrast Sensitivity on the Cone Contrast Test (CCT, Innova Systems, Inc.)

Time Frame: This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.

This computer test measures the lowest contrast (contrast sensitivity) to see red, green and blue cone specific letters.

Secondary Outcomes

  • Change in Visual Acuity Test at Low Contrast (Innova Systems, Inc)(This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.)
  • Change in Response Time on Black White Contrast Sensitivity Test (Innova Systems, Inc) Response Time(This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.)
  • Change in Black White Contrast Sensitivity (Innova Systems, Inc)(This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.)
  • Change in Response Time on Visual Acuity Test at Low Contrast (Innova Systems, Inc)(This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.)
  • Change in Color Naming Accuracy on Cone Contrast Color Naming test (CCNT)(This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.)
  • Change in Sensitivity on Cone Contrast Color Naming test (CCNT)(This test will occur prior to the intervention (Meibomian gland expression) and immediately after this intervention.)

Study Sites (1)

Loading locations...

Similar Trials